Tesamorelin (5mg Vial) Dosage Protocol
Quickstart Highlights
Tesamorelin 5mg dosage protocol is designed to stimulate growth hormone release and support body composition improvements through subcutaneous injections administered five days per week.
- Typical daily dosage range: 1 mg to 2 mg, Monday–Friday
- Subcutaneous injections, preferably in the morning (fasted state)
- Reconstitute with 1 mL for practical measurement (5 mg/mL concentration)
- Store lyophilized vials in the freezer; reconstituted solution in the refrigerator
- Allow for 2 consecutive off-days each week to maintain receptor sensitivity
Dosing & Reconstitution Guide
Educational guide for reconstitution and dosing protocol
Standard / Gradual Approach (1 mL = 5 mg/mL)
| Weeks | Daily Dosage (mg) | Units (per injection) |
|---|---|---|
| 1–4 | 1 mg (Mon–Fri) | 20 units |
| 5–8 | 1 mg (Mon–Fri) | 20 units |
A moderate protocol of 1 mg daily (5 days/week), using 1 mL of bacteriostatic water to achieve a 5 mg/mL concentration. Each 1 mg dose corresponds to 0.2 mL (20 units) on a 100-unit insulin syringe.
- Draw 1.0 mL of bacteriostatic water into a sterile syringe.
- Inject slowly along the vial wall to reduce foaming.
- Gently swirl until the powder dissolves—avoid vigorous shaking.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Advanced / Aggressive Approach (1 mL = 5 mg/mL)
| Weeks | Daily Dosage (mg) | Units (per injection) |
|---|---|---|
| 1–4 | 2 mg (Mon–Fri) | 40 units |
| 5–8 | 2 mg (Mon–Fri) | 40 units |
A more intensive protocol at 2 mg daily (5 days/week). With 1 mL of reconstitution, each 2 mg dose equals 0.4 mL (40 units). Note that each vial contains 5 mg total; advanced users may need multiple vials per week.
- Draw 1.0 mL of bacteriostatic water into a sterile syringe.
- Slowly inject along the vial wall to minimize foam.
- Gently roll/swirl; avoid shaking vigorously.
- Store the reconstituted solution at 2–8 °C (refrigerator), protected from light.
Protocol Overview
A concise summary of this daily (Monday–Friday) regimen.
- Goal: Boost endogenous growth hormone release and improve body composition
- Schedule: Daily subcutaneous injections (5x/week) for 8–16 weeks
- Dose Range: 1 mg to 2 mg per day (5 mg to 10 mg total weekly)
- Reconstitution: Use 1 mL for user-friendly measurements (5 mg/mL)
- Storage: Keep lyophilized vials frozen; refrigerate after mixing
Dosing Protocol
Suggested daily injection approach for optimal GH stimulation.
- Daily Dose: 1 mg (standard) or 2 mg (advanced), Monday–Friday
- Frequency: Subcutaneous injection once per day
- Cycle Length: 8–16 weeks (longer if desired)
- Washout Period: Weekends off (2 days) to maintain receptor sensitivity
- Timing: Preferably in the morning (fasted state)
Storage Instructions
Proper storage ensures peptide integrity.
- Lyophilized: Freeze until mixing (−20°C or below)
- Reconstituted: Refrigerate at 2–8°C
- Use within 30 days of reconstitution
- Avoid repeated freeze-thaw cycles
Supplies Needed
Ensure you have these on hand for an 8–16 week protocol.
- Peptide Vials (5 mg each):
• Standard (1 mg/day, 5 days/wk = 5 mg/wk): ~1 vial per week
• Advanced (2 mg/day, 5 days/wk = 10 mg/wk): ~2 vials per week
Adjust total vials for desired cycle length (e.g., 8, 12, or 16 weeks). - Insulin Syringes: One syringe per injection day
• 8 wks ≈ 40 syringes (standard or advanced) - Bacteriostatic Water: 1× 30 mL (sufficient for multiple vials)
- Alcohol Swabs: 1 box for cleaning stoppers & injection sites
Important Notes
Practical tips to enhance safety and efficacy.
- Always use sterile insulin syringes; rotate injection sites to avoid tissue damage.
- Administer in the morning (fasted) for optimal GH response.
- Allow for 2 consecutive off-days per week to maintain receptor sensitivity.
- Monitor for any adverse reactions; consult a professional if concerns arise.
How This Works
Tesamorelin is a growth hormone-releasing hormone (GHRH) analog that prompts the pituitary to release growth hormone.
- GH Release: Increases pituitary output of growth hormone
- Metabolic Impact: Potentially aids in reducing visceral fat and improving body composition
- Additional Research: Explored for muscle support and fat loss beyond HIV-related lipodystrophy
Potential Benefits & Side Effects
Most users observe improved GH profiles, though individual responses vary.
- May help decrease abdominal fat in HIV-associated lipodystrophy
- Could support lean mass and overall metabolic function
- Common mild sides: injection site irritation, swelling, or redness
- Rarely, joint discomfort, nausea, or headaches can occur
Lifestyle Factors
Complementary strategies for maximizing results.
- Combine with a balanced, protein-rich diet and regular exercise
- Prioritize sleep and stress management to optimize hormonal balance
- Stay hydrated and follow consistent injection times for best outcomes
Injection Technique
Simple guidelines for safe daily injections.
- Clean vial rubber stopper & injection site with alcohol swabs
- Insert needle at a 45–90° angle into subcutaneous tissue
- Inject slowly & rotate sites (abdomen, thigh, etc.)
Recommended Source
We recommend Pure Lab Peptides for high-purity Tesamorelin.
Why Pure Lab Peptides?
- Verifies ≥99% purity through independent lab testing
- Trusted by researchers seeking reliable results
- Follows rigorous manufacturing standards for consistent quality
Important Note
This guide is for educational purposes only. Always consult a qualified healthcare provider before starting or modifying any therapy.
References
-
Drugs.com
– Egrifta SV dosage details -
PDR
– Egrifta (tesamorelin) drug summary -
FDA Document
– Official labeling for Egrifta -
Medscape
– Egrifta (tesamorelin) dosing overview -
Drugs.com
– Tesamorelin dosage information -
Egrifta SV Official PDF
– IFU for Egrifta SV -
FDA Document
– Tesamorelin labeling (2013) -
Egrifta SV Official Resource
– Reconstitution guidelines -
NCBI Books
– Tesamorelin pharmacology overview -
NCBI Books
– Additional GHRH analog details -
Drugs.com
– Egrifta comprehensive dosage -
JCEM (OUP)
– Tesamorelin trial in J Clin Endocrinol -
Drugs.com
– Monograph on tesamorelin -
Health Canada Document
– Tesamorelin product PDF -
JAMA
– Clinical article on tesamorelin -
MedlinePlus
– Tesamorelin consumer information -
Mayo Clinic
– Tesamorelin route and description -
Egrifta SV Official Resource
– Dosing information from manufacturer -
PMC
– Article on tesamorelin research (PMC6981288) -
PMC
– Tesamorelin study (PMC6766405)